2021-03-17 15:44Press release

RedHeart study proves improved health-related quality of life (HRQOL) using the Coala groundbreaking digital technology

Largest clinical study to date on women-only demonstrates that ECG with real-time response to patients helps reduce symptoms of palpitations and increase quality of life.

PRESS RELEASE, Uppsala, Sweden, March 17, 2021 – Coala Life today announced the results of the RedHeart Study where the Coala Heart Monitor (“Coala”) was used to evaluate 821 women with palpitation symptoms over 60 days. Goals were to determine to what degree direct feedback of the underlying heart rhythm, such as provided by the Coala through its instant ECG analysis could help to reduce symptoms caused by palpitations and increase health-related quality of life (HRQOL).

The study demonstrated that the use of ECG with instant feedback during symptoms decreased the degree of palpitation symptoms, decreased levels of depression and anxiety, and increased HRQOL in women.

“The RedHeart study proves the efficacy of the Coala and its real-time ECG for long-term remote monitoring and helping patients that suffer from common heart palpitations. The study results are enlightening for the many women with palpitation issues that often cause anxiety and as research has shown, are often challenging to being correctly diagnosed by healthcare providers”, comments Dan Pitulia, CEO of Coala Life.

Participants were recruited digitally and remotely from all over Sweden with different socioeconomic backgrounds in the age span of 20-88 years. Participants responded to validated questionnaires related to symptoms, anxiety and depression, and HRQOL before and after the 60-day monitoring term.

Over 200,000 individual ECG tracings were generated by the 2-lead Coala and automatically analyzed by algorithms. The entire study was carried out remotely, including recruitment and inclusion of all participants without having to meet any healthcare staff.

The prospective, observational RedHeart study was conducted by researchers and physicians at Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden. The results were published by the European Society of Cardiology in the March 2021 issue of the European Journal of Cardiovascular Nursing.

The study is accessible with free access through https://doi.org/10.1093/eurjcn/zvaa031

For more info:
Dan Pitulia, CEO Coala Life AB, +46 70 972 08 38, dan.pitulia@coalalife.com


About Coala Life

Coala Life is a Swedish digital health venture focused on cardiac diagnostics and digital health. The company has developed a portfolio of patented CE- and FDA-cleared medical products and services for user-centered digital remote monitoring and analysis of the heart based on advanced and smart algorithms. Coala’s solutions enable analysis, remote monitoring, more effective cardiac assessments and integrated care services, all in real time. Coala Life has raised in excess of USD 20 million and was named one of five global Cool Vendors by Gartner Group in 2018 and recognized as of the 100 Global Leaders in Digital Health by the Journal of mHealth. Follow your Heart®. For more information see www.coalalife.com

Contacts

Coala Life
Coala Life